|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
��ֲ������� |
|
�� |
|
���� |
| ��������������� | |
|
��� |
|
֣�� |
| PubMed | |
|
Article by ZHAO Lu |
|
Article by ZHENG Min |
��ֲ���������Ƥ�����ּ����ƽ�չ
���, ֣��
�㽭��ѧҽѧԺ�����ڶ�ҽԺƤ���� ���� 310009
��ֲ��������dz������������Ѫ��ϸ����ֲ�����һ���ۼ������ٵ������Լ�����������ֲ���㷺��չ,��Ч���α�����Ϊ�о��ȵ㡣��ֲ���������Ҫ�����ڲ�������Ƥ��������������ϵͳӦ����Ƥ�ʼ���Ϊ��ͳһ���Ʒ�,����������Ƥ�ʼ��ػ�����������صIJ�����Ӧ,���,�����µ����ƴ�ʩ�о������ձ��ע��
Cutaneous Manifestations and Advances in the Treatment of Graft-versus-host Disease
Department of Dermatology and Venereology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China
Department of Dermatology and Venereology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China
Graft-versus-host disease (GVHD), an immunologic disease involving multiple organs, often occurs in long-term survivors of allogeneic stem cell transplantation. With the rapid development of transplantation, how to effectively prevent the occurence and manage the process of GVHD has become the hotspot of current investigations. There are cutaneous manifestations and they often occur in the early stage. Systemic corticosteroids are the traditional first-line therapy, however, considering the severe side effects of the long term use of corticosteroids, investigators are now working to search new theraputic methods for GVHD. Cutaneous manifestations and recent advances in the treatment of GVHD are discussed below.
[2] Sanli H,Arat M,Oskay T,et al.Evaluation of nail involvement in patients with chronic cutaneous graft versus host disease:a single-center study from Turkey.Int J Dermatol,2004,43:176-180.
[3] Penas PF,Jones-Caballero M,Aragues M,et al.Sclerodermatous graft-vs-host disease:clinical and pathological study of 17 patients.Arch Dermatol,2002,138:924-934.
[4] Selvaag E,Jacobsen N,Thomsen K.Facial premature ageing as a side-effect following bone marrow transplantation.J Eur Acad Dermatol Venereol,2003,17:566-568.
[5] Foss FM,DiVenuti GM,Chin K,et al.Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease:analysis of response and survival incorporating prognostic factors.Bone Marrow Transplant,2005,35:1187-1193.
[6] Garban F,Drillat P,Makowski C,et al.Extracorporeal chemophototherapy for the treatment of graft-versus-host disease:hematologic consequences of short-term,intensive courses.Haematologica,2005,90:1096-1101.
[7] Ziemer M,Thiele JJ,Gruhn B,et al.Chronic cutaneous graft-versus-host disease in two children responds to UVA1 therapy:improvement of skin lesions,joint mobility,and quality of life.J Am Acad Dermatol,2004,51:318-319.
[8] Wetzig T,Sticherling M,Simon JC,et al.Medium dose long-wavelength ultraviolet A (UVA1) phototherapy for the treatment of acute and chronic graft-versus-host disease of the skin.Bone Marrow Transplant,2005,35:515-519.
[9] Wolff D,Anders V,Corio R,et al.Oral PUVA and topical steroids for treatment of oral manifestations of chronic graft-vs.-host disease.Photodermatol Photoimmunol Photomed,2004,20:184-190.
[10] Brenner M,Herzinger T,Berking C,et al.Phototherapy and photochemotherapy of sclerosing skin diseases.Photodermatol Photoimmunol Pbotomed,2005,21:157-165.
[11] Chor A,de Azevedo AM,Maiolino A,et al.Successful treatment of oral lesions of chronic lichenoid graft-vs.-host disease by the addition of low-level laser therapy to systemic immunosuppression.Eur J Haematol,2004,72:222-224.
[12] Patriarca F,Sperotto A,Damiani D,et al.Infliximab treatment for steroid-refractory acute graft-versus-host disease.Haematologica,2004,89:1352-1359.
[13] Wolff D,Roessler V,Steiner B,et al.Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept.Bone Marrow Transplant,2005,35:1003-1010.
[14] Carpenter PA,Lowder J,Johnston L,et al.A phase �� multicenter study of visilizumab,humanized anti-CD3 antibody,to treat steroid-refractory acute graft-versus-host disease.Biol Blood Marrow Transplant,2005,11:465-471.
[15] Canninga-van Dijk MR,van der Straaten HM,Fijnheer R,et al.Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease.Blood,2004,104:2603-2606.
[16] Ziemer M,Gruhn B,Thiele JJ,et al.Treatment of extensive chronic cutaneous graft-versus-host disease in an infant with topical pimecrolimus.J Am Acad Dermatol,2004,50:946-948.
[17] Elad S,Or R,Resnick I,Shapira MY.Topical tacrolimus-a novel treatment alternative for cutaneous chronic graft-versus-host disease.Transpl Int,2003,16:665-670.
[18] Sanchez AR,Sheridan P J,Rogers RS.Successful treatment of oral lichen planus-like chronic graft-versus-host disease with topical tacrolimus:a case report.J Periodontol,2004,75:613-619.
[19] Ho VT,Zahrieh D,Hochberg E,et al.Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.Blood,2004,15,104:1224-1226.
[20] Bolanos-Meade J,Jacobsohn DA,Margolis J,et al.Pentostatin in steroid-refractory acute graft-versus-host disease.J Clin Oncol,2005,23:2661-2668.
[21] Le Blanc K,Rasmusson I,Sundberg B,et al.Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells.Lancet,2004,363:1439-1441.